title: Blood pressure control for diabetic retinopathy.
abstract: BACKGROUND
  Diabetic retinopathy is a common complication of diabetes and a leading cause of visual impairment and blindness. Research has established the importance of blood glucose control to prevent development and progression of the ocular complications of diabetes. Simultaneous blood pressure control has been advocated for the same purpose, but findings reported from individual studies have supported varying conclusions regarding the ocular benefit of interventions on blood pressure.
  
  
  OBJECTIVE
  The primary aim of this review was to summarize the existing evidence regarding the effect of interventions to control or reduce blood pressure levels among diabetics on incidence and progression of diabetic retinopathy, preservation of visual acuity, adverse events, quality of life, and costs. A secondary aim was to compare classes of anti-hypertensive medications with respect to the same outcomes.
  
  
  METHODS
  We searched a number of electronic databases including CENTRAL as well as ongoing trial registries. We last searched the electronic databases on 25 April 2014. We also reviewed reference lists of review articles and trial reports selected for inclusion. In addition, we contacted investigators of trials with potentially pertinent data.
  
  
  METHODS
  We included in this review randomized controlled trials (RCTs) in which either type 1 or type 2 diabetic participants, with or without hypertension, were assigned randomly to intense versus less intense blood pressure control, to blood pressure control versus usual care or no intervention on blood pressure, or to different classes of anti-hypertensive agents versus placebo.
  
  
  METHODS
  Pairs of review authors independently reviewed titles and abstracts from electronic and manual searches and the full text of any document that appeared to be relevant. We assessed included trials independently for risk of bias with respect to outcomes reported in this review. We extracted data regarding trial characteristics, incidence and progression of retinopathy, visual acuity, quality of life, and cost-effectiveness at annual intervals after study entry whenever provided in published reports and other documents available from included trials.
  
  
  RESULTS
  We included 15 RCTs, conducted primarily in North America and Europe, that had enrolled 4157 type 1 and 9512 type 2 diabetic participants, ranging from 16 to 2130 participants in individual trials. In 10 of the 15 RCTs, one group of participants was assigned to one or more anti-hypertensive agents and the control group received placebo. In three trials, intense blood pressure control was compared to less intense blood pressure control. In the remaining two trials, blood pressure control was compared with usual care. Five of the 15 trials enrolled type 1 diabetics, and 10 trials enrolled type 2 diabetics. Six trials were sponsored entirely by pharmaceutical companies, seven trials received partial support from pharmaceutical companies, and two studies received support from government-sponsored grants and institutional support.Study designs, populations, interventions, and lengths of follow-up (range one to nine years) varied among the included trials. Overall, the quality of the evidence for individual outcomes was low to moderate. For the primary outcomes, incidence and progression of retinopathy, the quality of evidence was downgraded due to inconsistency and imprecision of estimates from individual studies and differing characteristics of participants.For primary outcomes among type 1 diabetics, one of the five trials reported incidence of retinopathy and one trial reported progression of retinopathy after 4 to 5 years of treatment and follow-up; four of the five trials reported a combined outcome of incidence and progression over the same time interval. Among type 2 diabetics, 5 of the 10 trials reported incidence of diabetic retinopathy and 3 trials reported progression of retinopathy; one of the 10 trials reported a combined outcome of incidence and progression during a 4- to 5-year follow-up period. One trial in which type 2 diabetics participated had reported no primary (or secondary) outcome targeted for this review.The evidence from these trials supported a benefit of more intensive blood pressure control intervention with respect to 4- to 5-year incidence of diabetic retinopathy (estimated risk ratio (RR) 0.80; 95% confidence interval (CI) 0.71 to 0.92) and the combined outcome of incidence and progression (estimated RR 0.78; 95% CI 0.63 to 0.97). The available evidence provided less support for a benefit with respect to 4- to 5-year progression of diabetic retinopathy (point estimate was closer to 1 than point estimates for incidence and combined incidence and progression, and the CI overlapped 1; estimated RR 0.88; 95% CI 0.73 to 1.05). The available evidence regarding progression to proliferative diabetic retinopathy or clinically significant macular edema or moderate to severe loss of best-corrected visual acuity did not support a benefit of intervention on blood pressure: estimated RRs and 95% CIs 0.95 (0.83 to 1.09) and 1.06 (0.85 to 1.33), respectively, after 4 to 5 years of follow-up. Findings within subgroups of trial participants (type 1 and type 2 diabetics; participants with normal blood pressure levels at baseline and those with elevated levels) were similar to overall findings.The adverse event reported most often (7 of 15 trials) was death, yielding an estimated RR 0.86 (95% CI 0.64 to 1.14). Hypotension was reported from three trials; the estimated RR was 2.08 (95% CI 1.68 to 2.57). Other adverse ocular events were reported from single trials.
  
  
  CONCLUSIONS
  Hypertension is a well-known risk factor for several chronic conditions in which lowering blood pressure has proven to be beneficial. The available evidence supports a beneficial effect of intervention to reduce blood pressure with respect to preventing diabetic retinopathy for up to 4 to 5 years. However, the lack of evidence to support such intervention to slow progression of diabetic retinopathy or to prevent other outcomes considered in this review, along with the relatively modest support for the beneficial effect on incidence, weakens the conclusion regarding an overall benefit of intervening on blood pressure solely to prevent diabetic retinopathy.
authors: Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, 985540 Nebraska Medical Center, Omaha, Nebraska, USA, 68198-5540.
authors: Diana V
authors: DV
authors: Do
authors: Xue
authors: X
authors: Wang
authors: Satyanarayana S
authors: SS
authors: Vedula
authors: Michael
authors: M
authors: Marrone
authors: Gina
authors: G
authors: Sleilati
authors: Barbara S
authors: BS
authors: Hawkins
authors: Robert N
authors: RN
authors: Frank
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003930:Diabetic Retinopathy / Q000453:epidemiology / Q000517:prevention & control*; D018450:Disease Progression; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D015994:Incidence; D016032:Randomized Controlled Trials as Topic
chemical_list: D000959:Antihypertensive Agents
references: Diabetologia. 1996 Dec;39(12):1554-61
references: 8960842
references: JAMA. 2007 Aug 22;298(8):902-16
references: 17712074
references: N Engl J Med. 1993 Sep 30;329(14):977-86
references: 8366922
references: Diabetes Care. 1998 Aug;21(8):1230-5
references: 9702425
references: Arch Ophthalmol. 1985 Dec;103(12):1796-806
references: 2866759
references: Diabetes Care. 2004 May;27(5):1047-53
references: 15111519
references: Arch Intern Med. 1989 Nov;149(11):2427-32
references: 2684072
references: Am J Cardiol. 1995 May 1;75(14):894-903
references: 7732997
references: J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2 Suppl):S25-8
references: 17199216
references: Diabet Med. 2011 Mar;28(3):345-51
references: 21309844
references: Diabetologia. 1991 Dec;34(12):877-90
references: 1778353
references: Ophthalmology. 1991 May;98(5 Suppl):786-806
references: 2062513
references: Ophthalmology. 1997 Feb;104(2):252-60
references: 9052629
references: Lancet. 2008 Oct 18;372(9647):1394-402
references: 18823656
references: Diabetes Care. 1998 Jan;21(1):157-9
references: 9538987
references: Kidney Int. 2002 Mar;61(3):1086-97
references: 11849464
references: Arch Ophthalmol. 2004 Apr;122(4):546-51
references: 15078673
references: Eur J Ophthalmol. 1991 Jul-Sep;1(3):131-6
references: 1841669
references: Am J Cardiol. 2007 Jun 18;99(12A):21i-33i
references: 17599422
references: Chin Med J (Engl). 2012 Jan;125(2):287-92
references: 22340561
references: BMC Pediatr. 2009 Dec 17;9:79
references: 20017932
references: Lancet. 2008 Oct 18;372(9647):1385-93
references: 18823658
references: Ophthalmology. 2003 May;110(5):941-7
references: 12750094
references: Diabetologia. 2001 Dec;44(12):2203-9
references: 11793022
references: Lancet. 1997 Jun 21;349(9068):1787-92
references: 9269212
references: Diabetologia. 2001 Sep;44(9):1118-20
references: 11596665
references: Lancet. 1998 Jun 13;351(9118):1755-62
references: 9635947
references: BMJ. 1995 Oct 14;311(7011):973-7
references: 7580637
references: Diabetologia. 2005 May;48(5):868-77
references: 15834550
references: BMJ. 2002 Oct 19;325(7369):860
references: 12386035
references: Diabetes Care. 2002 Aug;25(8):1320-5
references: 12145228
references: Ophthalmology. 1996 Sep;103(9):1438-42
references: 8841303
references: Endocr Pract. 2006 Jan-Feb;12 Suppl 1:89-92
references: 16627389
references: Nephrol Dial Transplant. 1998 Oct;13(10):2547-52
references: 9794557
references: Diabet Med. 1994 Oct;11(8):773-82
references: 7851072
references: JAMA. 2010 Aug 11;304(6):649-56
references: 20699456
references: Diabet Med. 2001 Apr;18(4):288-94
references: 11437859
references: Br J Ophthalmol. 1999 Sep;83(9):1083-7
references: 10460781
references: BMJ. 1998 Sep 12;317(7160):720-6
references: 9732339
references: J Renin Angiotensin Aldosterone Syst. 2005 Mar;6(1):25-32
references: 16088848
references: Diabetes. 1969 May;18(5):285-91
references: 4894161
references: Diabetologia. 1999 Sep;42(9):1107-12
references: 10447523
references: Lancet. 1998 Sep 12;352(9131):837-53
references: 9742976
references: J Renin Angiotensin Aldosterone Syst. 2002 Dec;3(4):255-61
references: 12584669
references: Diabetologia. 2010 Mar;53(3):419-28
references: 20054522
references: Am J Cardiol. 2007 Jun 18;99(12A):90i-102i
references: 17599429
references: Diabetologia. 2011 Sep;54(9):2288-94
references: 21630126
references: Online J Curr Clin Trials. 1993 Nov 24;Doc No 104:[6250 words; 128 paragraphs]
references: 8305994
references: N Engl J Med. 2010 Jul 15;363(3):233-44
references: 20587587
references: Nefrologia. 2010;30(4):473-4
references: 20651891
references: Surv Ophthalmol. 2012 Jul-Aug;57(4):347-70
references: 22542913
references: Cochrane Database Syst Rev. 2015 Jan 31;1:CD006127
references: 25637717
references: J Hypertens Suppl. 2009 May;27(1):S3-8
references: 19483505
references: JAMA. 1993 Mar 10;269(10):1290-1
references: 8437309
references: Arch Ophthalmol. 1984 Apr;102(4):520-6
references: 6367724
references: Ophthalmology. 1989 Oct;96(10):1501-10
references: 2587045
references: Arch Ophthalmol. 2001 Jul;119(7):1050-8
references: 11448327
references: Control Clin Trials. 2003 Aug;24(4):442-61
references: 12865039
references: Acta Ophthalmol Scand. 1996 Aug;74(4):395-8
references: 8883558
references: Arch Ophthalmol. 2004 Nov;122(11):1631-40
references: 15534123
references: Diabetes Care. 2000 Apr;23 Suppl 2:B54-64
references: 10860192
references: Acta Ophthalmol. 2011 Dec;89(8):764-8
references: 20346089
references: J Diabetes Investig. 2011 Apr 7;2(2):101-3
references: 24843468
references: Diabetes Care. 2005 Feb;28(2):273-7
references: 15677778
references: Rev Med Chil. 2000 Oct;128(10):1085-92
references: 11349506
references: Diabetes Care. 2003 Jun;26(6):1731-7
references: 12766102
references: Ophthalmology. 1991 May;98(5 Suppl):823-33
references: 2062515
references: Ann Ophthalmol. 1992 Mar;24(3):99-103
references: 1570931
references: Cochrane Database Syst Rev. 2014 Oct 24;(10):CD007419
references: 25342124
references: N Engl J Med. 2003 Jan 30;348(5):383-93
references: 12556541
references: Arch Ophthalmol. 2004 Apr;122(4):477-85
references: 15078664
references: Arch Ophthalmol. 1984 Apr;102(4):527-32
references: 6367725
references: Ugeskr Laeger. 1999 Feb 15;161(7):949-52
references: 10051804
references: Graefes Arch Clin Exp Ophthalmol. 2004 Jul;242(7):535-40
references: 14991334
references: Invest Ophthalmol Vis Sci. 1985 Jul;26(7):983-91
references: 2409053
references: Ophthalmology. 2004 Jan;111(1):53-61
references: 14711714
references: Invest Ophthalmol Vis Sci. 1998 Feb;39(2):233-52
references: 9477980
references: Diabetes Care. 2008 Apr;31(4):708-13
references: 18184903
references: Diabetes Care. 2001 Jul;24(7):1275-9
references: 11423515
references: Br J Ophthalmol. 2002 Apr;86(4):365-7
references: 11914198
references: Diabetes Care. 2003 Jan;26(1):76-81
references: 12502661
references: Br J Ophthalmol. 2015 Jan;99(1):64-8
references: 25091950
references: Diabetologia. 1996 Dec;39(12):1646-54
references: 8960857
references: N Engl J Med. 2009 Jul 2;361(1):40-51
references: 19571282
references: Arch Ophthalmol. 2010 Mar;128(3):312-8
references: 20212201
references: Ophthalmology. 2002 Jul;109(7):1225-34
references: 12093643
references: Am J Kidney Dis. 1992 Dec;20(6):653-7
references: 1462999
references: Lancet. 1998 Dec 19-26;352(9145):1978-81
references: 9872248
references: Ophthalmology. 1991 May;98(5 Suppl):766-85
references: 2062512
references: Aging Trends. 2001 Mar;(2):1-8
references: 11894223
references: N Engl J Med. 2004 Nov 4;351(19):1941-51
references: 15516697
references: N Engl J Med. 1998 Mar 5;338(10):645-52
references: 9486993
references: Diabetologia. 2001 Feb;44(2):156-63
references: 11270671
references: Diabetes Care. 1999 Jul;22(7):1125-36
references: 10388978
references: Contemp Clin Trials. 2007 Jan;28(1):6-17
references: 17030155
references: Diabetologia. 2009 Oct;52(10):2027-36
references: 19633827
references: BMJ. 1998 Sep 12;317(7160):713-20
references: 9732338
references: Diabet Med. 2002 Nov;19(11):924-31
references: 12421429
references: N Engl J Med. 2008 Oct 9;359(15):1565-76
references: 18784091
references: Ophthalmology. 1978 Jan;85(1):82-106
references: 345173
references: Lancet. 2007 Sep 8;370(9590):829-40
references: 17765963
references: Ann Ophthalmol. 1993 Aug;25(8):284-9
references: 8239321
references: J Hypertens. 2006 Feb;24(2):403-8
references: 16508590
references: Diabetes Care. 2014 Jul;37(7):2015-23
references: 24784827
references: Arch Ophthalmol. 1996 Sep;114(9):1079-84
references: 8790092
references: Int J Clin Pract. 2011 Feb;65(2):148-53
references: 21235695
references: JAMA. 2002 May 15;287(19):2563-9
references: 12020338
references: Am J Hypertens. 2006 Dec;19(12):1241-8
references: 17161769
references: JAMA. 1988 Nov 18;260(19):2864-71
references: 3184351
references: Arch Ophthalmol. 2003 Feb;121(2):245-51
references: 12583792
references: Hypertension. 2011 Nov;58(5):776-83
references: 21931073
references: Diabetes. 2005 Feb;54(2):527-33
references: 15677511
references: Arch Ophthalmol. 2004 Apr;122(4):552-63
references: 15078674
references: Diabetes Care. 2004 Jan;27 Suppl 1:S84-7
references: 14693935
references: Cochrane Database Syst Rev. 2011 May 11;(5):CD008214
references: 21563165
references: Am J Cardiol. 2007 Jun 18;99(12A):44i-55i
references: 17599425
references: Br J Ophthalmol. 1989 Feb;73(2):88-94
references: 2930763
references: Lancet. 1998 Jan 3;351(9095):28-31
references: 9433426
references: Ophthalmologica. 1999;213(3):176-82
references: 10202291
references: Lancet. 2000 Jan 22;355(9200):253-9
references: 10675071
references: Diabet Med. 2002 May;19(5):385-92
references: 12027926
references: Clin Exp Pharmacol Physiol. 2001 Dec;28(12):1108-11
references: 11903327
references: Ophthalmology. 1981 Jul;88(7):583-600
references: 7196564
references: Ophthalmology. 2010 Jun;117(6):1064-1077.e35
references: 20427088
references: Lancet. 2010 Aug 7;376(9739):419-30
references: 20594588
references: Graefes Arch Clin Exp Ophthalmol. 1990;228(6):505-9
references: 2265765
references: Dev Ophthalmol. 1981;2:248-61
references: 7262408
references: Diabet Med. 2002 Jan;19(1):27-34
references: 11869300
references: J Renin Angiotensin Aldosterone Syst. 2002 Dec;3(4):262-9
references: 12584670
references: Diabetologia. 2001 Sep;44 Suppl 2:S22-30
references: 11587046
references: Diabet Med. 2001 Jun;18(6):438-44
references: 11472461
references: N Engl J Med. 2004 Jan 1;350(1):48-58
references: 14702427
references: J Renin Angiotensin Aldosterone Syst. 2003 Jun;4(2):96-9
references: 12806591
references: J Med Libr Assoc. 2006 Apr;94(2):130-6
references: 16636704
references: Metabolism. 1998 Dec;47(12 Suppl 1):28-33
references: 9867068
references: N Engl J Med. 2008 Jun 12;358(24):2560-72
references: 18539916
references: Geriatr Gerontol Int. 2012 Apr;12 Suppl 1:7-17
references: 22435936
references: J Ophthalmol. 2010;2010:106384
references: 20628590
references: BMJ. 1998 Sep 12;317(7160):703-13
references: 9732337
references: Ophthalmology. 2006 Dec;113(12):2231-6
references: 16996597
references: N Engl J Med. 2011 Jan 13;364(2):188-9
references: 21226603
references: Diabetes Care. 1999 Jan;22(1):99-111
references: 10333910
references: Am J Cardiol. 2007 Jun 18;99(12A):103i-111i
references: 17599420
references: J Diabetes Complications. 2002 Nov-Dec;16(6):377-81
references: 12477620
references: Kidney Int. 2012 Mar;81(6):586-94
references: 22166848
references: Lancet. 1999 Feb 20;353(9153):617-22
references: 10030326
references: Diabet Med. 2005 Jul;22(7):882-8
references: 15975103